The short version
4 companies supply this market — a reasonable cushion if one runs into trouble. It is in shortage right now.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Precedex
Dexmedetomidine Hydrochloride · DEXMEDETOMIDINE HYDROCHLORIDE 100 ug/mL · Injection, Solution, Concentrate · Intravenous · Hospira, Inc.
NDC 00409-1638-02 · 25 VIAL in 1 TRAY / 2 mL in 1 VIAL · NDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$150.00
Reported to Texas DSHS · 2026 annual filing · Pfizer Inc.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicaid spend (2025)
$18,999
2,176 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- Hospira, Inc.United Statesanalysis · label · manufacture · pack
- Hospira, Inc.United Statesanalysis · label · manufacture · pack
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA021038
- TE code
- AP
- Approval date
- Dec 17, 1999
- Patents / exclusivity
- 38 patents, 0 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| patent | 8455527*PED | Jul 4, 2032 |
| patent | 8242158*PED | Jul 4, 2032 |
| patent | 8338470*PED | Jul 4, 2032 |
| patent | 8455527*PED | Jul 4, 2032 |
| patent | 8242158*PED | Jul 4, 2032 |
| patent | 8338470*PED | Jul 4, 2032 |
| patent | 8648106*PED | Jul 4, 2032 |
| patent | 8648106*PED | Jul 4, 2032 |
| patent | 8648106*PED | Jul 4, 2032 |
| patent | 8242158*PED | Jul 4, 2032 |
| patent | 8455527*PED | Jul 4, 2032 |
| patent | 8338470*PED | Jul 4, 2032 |
Shortage history
- In shortage now — Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25)Apr 10, 2020month 77 — 4× the typical 20-month injectable shortage · model puts 24% odds it resolves within 6 months
- In shortage now — Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) (NDC 0409-1638-02)Apr 10, 2020month 77 — 4× the typical 20-month injectable shortage · model puts 24% odds it resolves within 6 months
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Dexmedetomidine Hydrochloride (Injection, Solution, Concentrate)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Baxter Healthcare Corporation | DEXMEDETOMIDINE HYDROCHLORIDE 100 ug/mL | Jul 15, 2026 | Sep 2, 2026 |
| Henry Schein, Inc. | DEXMEDETOMIDINE HYDROCHLORIDE 100 ug/mL | Jul 15, 2026 | Sep 2, 2026 |
| Hospira, Inc. | DEXMEDETOMIDINE HYDROCHLORIDE 100 ug/mL | Jul 15, 2026 | Sep 2, 2026 |
| Par Health USA, LLC | DEXMEDETOMIDINE HYDROCHLORIDE 100 ug/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Precedex — NDC 00409-1638-02," retrieved September 3, 2026, https://drugdashboards.com/drug/00409163802.
Free to cite with attribution — see how the data is put together.